{
    "root": "30161630-325a-4bb8-e063-6394a90a5e27",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Famotidine",
    "value": "20250311",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3000",
            "code": "SA1B764746"
        },
        {
            "name": "POLYETHYLENE GLYCOL 4000",
            "code": "4R4HFI6D95"
        },
        {
            "name": "FAMOTIDINE",
            "code": "5QZO15J2Z8"
        }
    ],
    "indications": "famotidine tablets indicated adult pediatric patients 40 kg greater treatment : active duodenal ulcer ( du ) . active gastric ulcer ( gu ) . active gastric ulcer ( gu ) . symptomatic nonerosive gastroesophageal reflux disease ( gerd ) . erosive esophagitis due gerd , diagnosed biopsy . famotidine tablets indicated adults : treatment pathological hypersecretory conditions ( e.g . , zollinger-ellison syndrome , multiple endocrine neoplasias ) . reduction risk duodenal ulcer recurrence .",
    "contraindications": "indication recommended ( 2.1 ) adult pediatric patients 40 kg greater active du 40 mg daily ; 20 mg twice daily active gastric ulcer 40 mg daily gerd 20 mg twice daily erosive esophagitis 20 mg twice daily ; 40 mg twice daily adults pathological hypersecretory condition 20 mg every 6 hours ; adjust patient needs ; maximum 160 mg every 6 hours risk reduction du reoccurrence 20 mg daily full prescribing information complete dosing information , including dosing renal impairment , recommended treatment duration . ( 2.1 , 2.2 ) ( 2.3 ) : take daily bedtime twice daily morning bedtime without food .",
    "warningsAndPrecautions": "famotidine tablets usp , 20 mg available beige , round , unscored , film-coated tablets , debossed `` 5728 `` one side “ teva ” side containing 20 mg famotidine , packaged bottles 60 tablets . bottles 60 : 20 mg ( ndc 68645-140-59 ) dispense well-closed , light-resistant container defined usp , child-resistant closure ( required ) . store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . avoid storage famotidine tablets temperatures 40°c ( 104°f ) . keep medications reach children .",
    "adverseReactions": "famotidine tablets contraindicated patients history serious hypersensitivity ( e.g . , anaphylaxis ) famotidine histamine-2 ( h2 ) receptor antagonists .",
    "indications_original": "Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: active duodenal ulcer (DU). \n                  \n                     active gastric ulcer (GU). \n                     active gastric ulcer (GU).\n                     symptomatic nonerosive gastroesophageal reflux disease (GERD). \n                     erosive esophagitis due to GERD, diagnosed by biopsy. \n                  \n                  Famotidine tablets are indicated in adults for the: \n                  \n                     treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). \n                     reduction of the risk of duodenal ulcer recurrence.",
    "contraindications_original": "Indication Recommended Dosage (2.1) Adult and Pediatric Patients 40 kg and greater Active DU 40 mg once daily; or 20 mg twice daily Active Gastric Ulcer 40 mg once daily GERD 20 mg twice daily Erosive Esophagitis 20 mg twice daily; or 40 mg twice daily Adults Pathological Hypersecretory Condition 20 mg every 6 hours; adjust to patient needs; maximum 160 mg every 6 hours Risk Reduction of DU Reoccurrence 20 mg once daily See full prescribing information for complete dosing information, including dosing in renal impairment, and recommended treatment duration. (2.1, 2.2) Administration (2.3): Take once daily before bedtime or twice daily in the morning and before bedtime with or without food.",
    "warningsAndPrecautions_original": "Famotidine Tablets USP, 20 mg are available as beige, round, unscored, film-coated tablets, debossed with \"5728\" on one side and “TEVA” on the other side containing 20 mg famotidine, packaged in bottles of 60 tablets.\n                  Bottles of 60: 20 mg (NDC 68645-140-59)\n                  \n                  Dispense in a well-closed, light-resistant container as defined in the USP, with a child-resistant closure (as required).\n                  Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Avoid storage of famotidine tablets at temperatures above 40°C (104°F).\n                  KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.",
    "adverseReactions_original": "Famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (H2) receptor antagonists."
}